Merck (MRK) Treasury Shares (2009 - 2026)
Merck (MRK) reported Treasury Shares of $63.7 billion for Q1 2026, up 7.32% year-over-year from $59.4 billion in Q1 2025, and up 1.19% quarter-over-quarter from $63.0 billion in Q4 2025.
Merck (MRK) Treasury Shares (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Treasury Shares data on file, last reported at $63.7 billion in Q1 2026.
- Treasury Shares for Q1 2026 came in at $63.7 billion, up 7.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.7 billion (up 7.32% YoY), and the FY2025 annual result was $63.0 billion, up 8.05% from the prior year.
- Treasury Shares rose to $63.7 billion in Q1 2026 per MRK's latest filing, from $63.0 billion in the prior quarter.
- Over five years, Treasury Shares peaked at $1.1 billion in Q1 2026 and troughed at $4.0 million in Q3 2023.
- A 5-year average of $872.4 million and a median of $1.0 billion in 2022 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares slipped 1.09% in 2022, then grew 8.05% in 2025.
- A 5-year view of Treasury Shares shows it stood at $56.5 billion in 2022, then gained by 1.7% to $57.4 billion in 2023, then gained by 1.48% to $58.3 billion in 2024, then grew by 8.05% to $63.0 billion in 2025, then gained by 1.19% to $63.7 billion in 2026.
- Business Quant data shows MRK's Treasury Shares at $63.7 billion in Q1 2026, $63.0 billion in Q4 2025, and $61.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 713.26 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 77.08 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 3.94 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 881.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -47.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.75 Bn |
| Mar 31, 2026 | 1.11 Bn |
| Mar 31, 2026 | 63.75 Bn |
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 63.00 Bn |
| Dec 31, 2025 | 1.10 Bn |
| Dec 31, 2025 | 63.00 Bn |
| Dec 31, 2025 | 1.10 Bn |
| Sep 30, 2025 | 1.09 Bn |
| Sep 30, 2025 | 61.80 Bn |
| Sep 30, 2025 | 61.80 Bn |
| Sep 30, 2025 | 1.09 Bn |
| Jun 30, 2025 | 60.50 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 60.50 Bn |
| Mar 31, 2025 | 13.00 Mn |
| Mar 31, 2025 | 59.40 Bn |
| Mar 31, 2025 | 59.40 Bn |
| Mar 31, 2025 | 13.00 Mn |